google plus one (home page)

Dupilumab (Dupixent) is the first new targeted therapy for CSU in over a decade.

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

New data highlight the potential of dupilumab, remibrutinib, and barzolvolimab to expand treatment options for patients with CSU unresponsive to current therapies.

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

The mildly elevated glycemia of prediabetes is a pathological condition with serious risks for those 77 million, says endocrinologist Samuel Dagogo-Jack, MD, DSc.

The positive topline data from the phase 3 ACHIEVE-1 trial suggest the small molecule GLP-1 mimetic could compete with blockbuster weekly injectables for reducing weight, A1c.